INTRODUCTION
It has recently been reported that enteral administration of tissue kallikrein (pig pancreatic kallikrein) can have an improving effect in several pathologic disorders such as an increase in sperm output and sperm motility in asthenozoospermia and Oligozoospermie (1) and a decrease of blood pressure in essential hypertension (2) . These findings suggest that tissue kallikrein can be absorbed intestinally in a biologically active form. That this is indeed the case was recently shown by other groups and by us (3,A,5), Here we present results on the intestinal absorption of enzymatically active tissue kallikrein obtained with a new experimental model.
METHODS

Perfusion of Intestinal Segments
Female Sprague-Dawley rats (270-310 g body weight) fasted for 18 h were operated as described by Windmuel1er and Spaeth (6) . Briefly, the rats were anesthetized with urethane (0.8 g/kg, i.p.) and the mesenterial vein draining a 8-10 cm segment of ileum as well as the Jugular vein and the carotid artery were cannulated. Ligatures were secured around each end of the selected segment. 0.2, 1.0 or 5.0 mg pig pancreatic kallikrein in 0.5 ml saline was injected into the closed loop. In control experiments C-14 labeled polyethylene glycol 4000 (50 nCi) was administered together with 0.5 ml saline or 5 mg kallikrein. Blood was collected from the intestinal vein for 60 min in 5 rain fractions. The blood lost was replaced by infusion of heparinized blood of donor rats into the jugular vein.
Analytical Procedures
Imrounoreactlve porcine pancreatic kallikrein was determined by a radioimmunoassay (7) . Kininogenase activities were measured by assaying the klnin released upon incubation of an aliquot of the respective sample with partially purified kininogen (8) .
Gel filtration experiments were performed using an Ultrogel AcA 44 column, 0.9 x 115 cm, eluted at a flow rate of 4.0 ml/h with 15 «M NaH2 P°4 ' 0.15 M NaCl, 0.01 M EDTA, 2 g NaN 3 /l, pH 7.4. Fractions of 0.9 ml were collected and analyzed for kininogenase activity and imraunoreactive pig pancreatic kallikrein.
RESULTS
Complex Formation of Pig Pancreatic Kallikrein (PPK) with Rat Plasma
Component s
Single plasma samples obtained during the absorption experiments were subjected to gel filtration. Imraunoreact!ve PPK was eluted in three peaks (Fig. 1 ). The peak maxima at fractions 32, 40 and 54 correspond to molecular masses of >130, 82 and 32 kDa. Since PPK has a molecular mass around 32 kDa the two peaks corresponding to higher molecular masses obviously represent complexes of PPK with components of rat plasma.
The immunoreactivities of the three species of PPK were not identical: when serial dilutions of single fractions of the three peaks were measured by radioimmunoassay the slopes of dose-response curves of the two complexes were not identical and they were also different from the slope of the standard curve.
The relative amounts of imraunoreactive PPK eluted in the three peaks varied when different plasma samples were subjected to gel filtration. It seems that the complex formation depends on different concentrations of the complex forming components of the individual rat plasmas or on not controllable conditions during sample preparation. Kininogenase activity was also eluted in three peaks ( Fig. 1 ), the highest activity was contained in the lmmunoreactivity peaks corresponding to the complexes, almost no activity was found In the peak of presumably free PPK (around fraction 54). The "free" PPK present in the sample obviously represents to a high degree an enzymatlcally inactive form, the active PPK is almost completely bound to plasma components. No kininogenase peaks were detectable when an identical gel filtration experiment was performed with a plasma sample which did not contain pig pancreatic kallikrein.
Radioimmunoassay of PPK in Rat Plasma
As a consequence of the complex formation the concentrations of PPK measured by radioimmunoassay are too low. This was shown by recovery experiments.
PPK was incubated with rat plasma in concentrations between 2 and 50 ng/ml and the PPK concentration determined by radioimmunoassay. The recoveries ranged between 25 and 8 percent. Thus, since the recoveries are dose dependent, a correction of the values is not possible.
Taken together, PPK and rat plasma components react under formation of complexes which have immunoreactlvitles different from and lower than free PPK. As a result, the value obtained as PPK concentration by radioimmunoassay varies with the dilution at which the sample is assayed and is significantly lower than the true PPK concentration in the sample. In addition, the ratio of the amounts of the three immunoreactive PPK species may vary from sample to sample, thus, even if the true concentrations of PPK in different plasma samples are identical the concentrations determined by radioimmunoassay may still be different.
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Fig. 2
Cumulative amount of pig pancreatic kallikrein in mesenterial venous blood of an intestinal segment after administration of 1.0 mg (four identically performed experiments, the amount of absorbed kallikrein is calculated per cm of the intestinal segment).
At these difIi^yit cannot be overcome and no o ..:, more reliable method to determine low concentrations of PPK in rat plasma is at hand. Therefore, in spite of the problems just presented we used the radioimmunoassay procedure in our studies. However, one has to keep in mind that the concentrations determined represent "imraunoreactivity equivalents" and not the true PPK concentrations. The true PPK concentrations will be significantly higher (certainly by a factor of ten) than the values presented here.
Intestinal Absorption of Porcine Pancreatic Kallikrein
Porcine pancreatic kallikrein was administered at dose levels of 0. The highest amount absorbed in one of the experiments was 0.05 Z of the administered dose. However, one has to consider that this amount was absorbed by only 10 cm of ileum whereas the total length of rat small intestine is about 100 cm and that the shape of the curves clearly demonstrates that the absorption was still in progress at the end of the experiment. In addition, as discussed above, the PPK concentrations in the plasma samples are highly underestimated by the radioimmunoassay. In a control experiment C-14 labelled PEG 4000 was administered together with 5 mg kallikrein. Only about 0.8 Z of the radioactivity were found in the blood which i s in the same range as in the absence of kallikrein. Thus, neither the experimental procedure nor the presence of the tissue kallikrein caused any significant unspecific permeability increase of the intestinal wall for high molecular substances.
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DISCUSSION
Earlier investigations (3) (4) (5) have shown that intestinal absorption of tissue kallikrein i s possible and some evidence has been presented suggesting that the absorbed kallikrein i s to some degree still enzymaticaliy active.
The experimental model employed here will allow to study the intestinal absorption of tissue kallikrein on a fully quantitative basis as soon as the problems of the radioimmunoassay can be overcome. The model i s well established for studies on the absorption of small molecules and seems to be equally well suited for investigations on the tissue kallikrein absorption though further control experiments will be necessary to confirm that the observed absorption i s not an artefact of the experimental setup.
The present studies corroborate the earlier findings (3) (4) and demonstrate clearly that tissue kallikrein can indeed be absorbed in an enzymaticaliy active form. Virtually all of the active tissue kallikrein i s bound to plasma components, but these kallikrein complexes still display kininogenase activity. I t is not clear whether this kininogenase activity i s intrinsic or due to a partial dissociation of the complexes under the conditions of our assay.
At present, nothing i s known on the nature and the physiological function of the complex forming proteins. One might speculate that they act both as inhibitors and as carriers for tissue kallikrelns preventing undesirable kinin release during the transport to the target site.
Compared to the administered dose the fraction of absorbed tissue kallikrein was quite low and it may be regarded as questionable whether such small amounts can exert the pharmacological effects observed in human. However, for the treatment of asthenozoospermia and oligozoospermia as well as of essential hypertension the tissue kallikrein is administered orally for at least several weeks and under these conditions a pharmacologically active level may build up.
